A5007032179- Head and Neck Cancer Studies
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ear and Head Tumors
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Radiopharmaceutical Chemistry and Applications
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Amino Acid Enzymes and Metabolism
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Moyamoya disease diagnosis and treatment
- PARP inhibition in cancer therapy
- Bone Tumor Diagnosis and Treatments
- Cervical Cancer and HPV Research
- Tumors and Oncological Cases
- Hepatocellular Carcinoma Treatment and Prognosis
- Facial Nerve Paralysis Treatment and Research
Institut Gustave Roussy
2017-2025
Centre Henri Becquerel
2024
Université de Rouen Normandie
2024
Inserm
2024
6002 Background: After promising results from the GORTEC TPEx phase II trial, role of taxane instead 5FU in 1st-line R/M HNSCC chemotherapy (CT) remained to be confirmed by comparing reference EXTREME regimen. Methods: Randomized (1:1), open-label trial. Main inclusion criteria were not suitable for locoregional treatment, age 18-70 years, PS <2, creatinine clearance >60ml/min, prior cisplatin <300 mg/m². Reference regimen (arm A: 6 cycles every 3 weeks (Q3W) 5FU–cisplatin-cetuximab...
Abstract Purpose: A first-in-human phase one study was conducted in nasopharyngeal carcinoma (NPC) patients to assess the safety and tolerability of VK-2019, a small molecule selective inhibitor Epstein-Barr virus Nuclear Antigen 1 (EBNA1). Patients Methods: Pharmacokinetic pharmacodynamic studies, including circulating tumor EBV DNA plasma levels, were performed. Twenty-three received VK-2019 orally once daily at doses ranging from 60 1800 mg using an accelerated titration design, with...
<div>AbstractPurpose:<p>A first-in-human phase I study was conducted in patients with nasopharyngeal carcinoma to assess the safety and tolerability of VK-2019, a small-molecule selective inhibitor Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1).</p>Patients Methods:<p>Pharmacokinetic pharmacodynamic studies were performed, including measurement EBV DNA plasma levels. Twenty-three received VK-2019 orally once daily at doses ranging from 60 1,800 mg using an...
<p>Supplementary tables</p>
<p>Supplement Figure 1</p>
<p>Supplement Figure 2</p>
6003 Background: ISA101b (peltopepimut-S) is a therapeutic vaccine targeting the HPV16 E6/E7 oncoproteins. The synthetic long peptides of induce specific expansion both CD4 + T-helper cells and CD8+ cytotoxic T-cells against E6/7 oncogenes 1 . Combination cemiplimab, an anti-PD-1 antibody with elicits synergistic anti-tumor effect 2 Methods: First second line naïve patients confirmed HPV16+ R/M OPC were randomized to treatment either (subcutaneously 100µg/peptide on days 1, 29, 50) or...
<p>supplementary materials</p>
<div>AbstractPurpose:<p>Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy a PD-1 inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in HNSCC. Sacituzumab govitecan (SG) Trop-2–directed antibody-drug conjugate approved patients certain solid tumors.</p>Patients Methods:<p>TROPiCS-03 (NCT03964727) an open-label, multicohort, phase II study evaluating SG...
Most salivary gland neoplasms are distinguished by specific recurrent gene fusions. Recently, a subset of pleomorphic adenomas (PAs) originated from the parotid harboring HMGA2::WIF1 fusion was described with canalicular adenoma-like morphology and greater propensity for recurrence carcinomatous transformation. This study delineates clinicopathological attributes 54 cases PAs exhibiting HMGA2 alterations, predominantly characterized fusion, alongside comparative analysis their morphological...
Abstract EGFR is a known driver of cancer growth, and leucine-rich, repeat-containing, G-protein coupled receptor 5 (LGR5) transmembrane expressed on stem cells. Petosemtamab human, common light chain, IgG1 bispecific antibody with ADCC-enhanced activity, targeting LGR5, which has shown potent antitumor activity in patient (pt)-derived HNSCC xenograft models. In the dose escalation part an ongoing phase 1/2 study, RP2D was established at 1500 mg Q2W, 4 week cycle (JCO 2021:39.3 Sup 62)....
Abstract Purpose: Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy a programmed death-1 (PD-1) inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in HNSCC. Sacituzumab govitecan (SG) Trop-2–directed antibody–drug conjugate approved patients certain solid tumors. Methods: TROPiCS-03 (NCT03964727) an open-label, multicohort, phase study evaluating SG tumors, including Adults...
6036 Background: Salvage chemotherapy after progression on immune checkpoint inhibitors (ICIs) was associated with an objective response rate (ORR) of 30% in patients (pts) recurrent/metastatic squamous cell carcinoma the head and neck (R/M SCCHN). We aimed to investigate efficacy taxanes + cetuximab (TC) +/- platinum pts R/M SCCHN who failed ICIs palliative setting. Methods: A retrospective study conducted at 7 French university hospitals. Eligibility criteria were treated ICI for SCCHN,...
6050 Background: Nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, demonstrated longer median overall survival (7.5 vs 5.1 months) and improved response (13.3% 5.8%) versus investigator choice chemotherapy (ICC) in patients with recurrent SCCHN after platinum failure CheckMate 141 (NCT02105636), a randomized, open-label Phase 3 trial. We screened peripheral blood lymphocytes (PBL) to identify biomarkers which may predict nivolumab. Methods: Paired baseline (day 1) on...
5572 Background: AcSé Pembrolizumab is a Phase 2, non-randomized parallel arms, multicentric basket trial investigating the efficacy and safety of pembrolizumab monotherapy in different cohorts patients with rare cancers (NCT03012620). Here we report results ovarian tumors cohort. Methods: Selected histotypes were all (incidence < 6/100,000/year). Main inclusion criteria age > 18, ECOG PS≤1, resistant disease to platinum based chemotherapy, systematic histological central review by...
ObjectivesTo analyse prognostic factors and survival outcomes of malignant tumors the external auditory canal, to investigate role regional surgery, adjuvant radiotherapy in early stages surgery operable T4 stage.SettingA retrospective analysis was conducted on all patients prospectively included national database French Expertise Network for Rare ENT Cancers (REFCOR) from January 2000 December 2016.Participants103 19 reference centers were included. A propensity score matching applied...
Importance Carotid blowout syndrome (CBS) is a rare life-threatening complication of head and neck cancer that requires either surgical or endovascular treatment such as carotid occlusion procedure stent-graft placement. CBS outcomes complications its management using placement remain unclear due to limited published data. Given this approach increasingly used, understanding efficacy associated risks paramount. Objective To evaluate the periprocedural postprocedural with for in patients...
<h3>Background</h3> Anticancer agents that render cancer cells susceptible to apoptosis and increase antitumor immunity may enhance clinical responses immune checkpoint inhibitors. In this phase 1b/2 trial, we investigated the activity safety of xevinapant, a first-in-class, potent, oral, small-molecule inhibitor proteins which restores cell sensitivity apoptosis, in combination with anti-PD-1 antibody nivolumab. <h3>Methods</h3> Eligible patients had histologically confirmed advanced or...
Abstract Background: The discovery of immune checkpoint blockers (ICB) has revolutionized the systemic approach treatment cancer. However, most patients receiving ICB do not derive benefit. Therefore, there is a crucial need to identify reliable predictive biomarkers response anti-PD-1/PD-L1 agents, both develop precision medicine in cancer immunotherapy and better understand mechanisms sensitivity resistance. One pathway that plays an important role regulation cell reactivity L-Arginine...